---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-026143"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2025-09-02T23:59:59+00:00"
generated_at: "2026-05-17T09:07:40.118386+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Enveric Biosciences moves HQ to Cambridge, MA; advances EB-003 toward IND in 2026

## Summary
- Effective Sept 2, 2025, principal executive offices changed to 245 First Street, 18th Floor, Cambridge, MA 02142.
- Relocation aims to leverage Boston biotech hub for talent, collaboration, and capital access.
- Lead candidate EB-003 (dual 5-HT2A/5-HT1B agonist) progressing toward IND; first-in-human trial anticipated in 2026.
- EB-003 designed to provide neuroplastogenic benefits without hallucinatory effects.

## SEC filing metadata
- accession: 0001641172-25-026143
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2025-09-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000164117225026143/0001641172-25-026143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000164117225026143/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-026143
- JSON: https://secwatch.observer/filing/0001641172-25-026143.json
- Plain text: https://secwatch.observer/filing/0001641172-25-026143.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.